Cargando…

Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism (†)

Conventional bivalent IgG antibodies targeting a subgroup of receptors of the TNF superfamily (TNFSF) including fibroblast growth factor-inducible 14 (anti-Fn14) typically display no or only very limited agonistic activity on their own and can only trigger receptor signaling by crosslinking or when...

Descripción completa

Detalles Bibliográficos
Autores principales: Aido, Ahmed, Zaitseva, Olena, Wajant, Harald, Buzgo, Matej, Simaite, Aiva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308961/
https://www.ncbi.nlm.nih.gov/pubmed/34371763
http://dx.doi.org/10.3390/pharmaceutics13071072
_version_ 1783728408972230656
author Aido, Ahmed
Zaitseva, Olena
Wajant, Harald
Buzgo, Matej
Simaite, Aiva
author_facet Aido, Ahmed
Zaitseva, Olena
Wajant, Harald
Buzgo, Matej
Simaite, Aiva
author_sort Aido, Ahmed
collection PubMed
description Conventional bivalent IgG antibodies targeting a subgroup of receptors of the TNF superfamily (TNFSF) including fibroblast growth factor-inducible 14 (anti-Fn14) typically display no or only very limited agonistic activity on their own and can only trigger receptor signaling by crosslinking or when bound to Fcγ receptors (FcγR). Both result in proximity of multiple antibody-bound TNFRSF receptor (TNFR) molecules, which enables engagement of TNFR-associated signaling pathways. Here, we have linked anti-Fn14 antibodies to gold nanoparticles to mimic the “activating” effect of plasma membrane-presented FcγR-anchored anti-Fn14 antibodies. We functionalized gold nanoparticles with poly-ethylene glycol (PEG) linkers and then coupled antibodies to the PEG surface of the nanoparticles. We found that Fn14 binding of the anti-Fn14 antibodies PDL192 and 5B6 is preserved upon attachment to the nanoparticles. More importantly, the gold nanoparticle-presented anti-Fn14 antibody molecules displayed strong agonistic activity. Our results suggest that conjugation of monoclonal anti-TNFR antibodies to gold nanoparticles can be exploited to uncover their latent agonism, e.g., for immunotherapeutic applications.
format Online
Article
Text
id pubmed-8308961
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83089612021-07-25 Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism (†) Aido, Ahmed Zaitseva, Olena Wajant, Harald Buzgo, Matej Simaite, Aiva Pharmaceutics Article Conventional bivalent IgG antibodies targeting a subgroup of receptors of the TNF superfamily (TNFSF) including fibroblast growth factor-inducible 14 (anti-Fn14) typically display no or only very limited agonistic activity on their own and can only trigger receptor signaling by crosslinking or when bound to Fcγ receptors (FcγR). Both result in proximity of multiple antibody-bound TNFRSF receptor (TNFR) molecules, which enables engagement of TNFR-associated signaling pathways. Here, we have linked anti-Fn14 antibodies to gold nanoparticles to mimic the “activating” effect of plasma membrane-presented FcγR-anchored anti-Fn14 antibodies. We functionalized gold nanoparticles with poly-ethylene glycol (PEG) linkers and then coupled antibodies to the PEG surface of the nanoparticles. We found that Fn14 binding of the anti-Fn14 antibodies PDL192 and 5B6 is preserved upon attachment to the nanoparticles. More importantly, the gold nanoparticle-presented anti-Fn14 antibody molecules displayed strong agonistic activity. Our results suggest that conjugation of monoclonal anti-TNFR antibodies to gold nanoparticles can be exploited to uncover their latent agonism, e.g., for immunotherapeutic applications. MDPI 2021-07-13 /pmc/articles/PMC8308961/ /pubmed/34371763 http://dx.doi.org/10.3390/pharmaceutics13071072 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Aido, Ahmed
Zaitseva, Olena
Wajant, Harald
Buzgo, Matej
Simaite, Aiva
Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism (†)
title Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism (†)
title_full Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism (†)
title_fullStr Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism (†)
title_full_unstemmed Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism (†)
title_short Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism (†)
title_sort anti-fn14 antibody-conjugated nanoparticles display membrane tweak-like agonism (†)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308961/
https://www.ncbi.nlm.nih.gov/pubmed/34371763
http://dx.doi.org/10.3390/pharmaceutics13071072
work_keys_str_mv AT aidoahmed antifn14antibodyconjugatednanoparticlesdisplaymembranetweaklikeagonism
AT zaitsevaolena antifn14antibodyconjugatednanoparticlesdisplaymembranetweaklikeagonism
AT wajantharald antifn14antibodyconjugatednanoparticlesdisplaymembranetweaklikeagonism
AT buzgomatej antifn14antibodyconjugatednanoparticlesdisplaymembranetweaklikeagonism
AT simaiteaiva antifn14antibodyconjugatednanoparticlesdisplaymembranetweaklikeagonism